Browse EX-10 agreements

​

Exhibit 10.15

MEIRAGTX HOLDINGS PLC

2026 EMPLOYMENT INDUCEMENT AWARD PLAN

RESTRICTED SHARE Unit Grant Notice

Capitalized terms not specifically defined in this Restricted Share Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2026 Employment Inducement Award Plan (as amended from time to time, the “Plan”) of MeiraGTx Holdings plc (the “Company”).

The Company has granted to the participant listed below (“Participant”) the Restricted Share Units described in this Grant Notice (the “RSUs”), subject to the terms and conditions of the Plan and the Restricted Share Unit Agreement attached as Exhibit A(the “Agreement”), both of which are incorporated into this Grant Notice by reference.

…

ACCELERANT HOLDINGS

ANNUAL BONUS PLAN

Adopted May 13, 2026

1.					General Plan Purpose and Structure

The purpose of the Accelerant Holdings Annual Bonus Plan (the “ABP”) is to motivate superior, focused, and prudent performance on the part of employees, including behaviors that drive collective success, for the ultimate benefit of shareholders and employees. The ABP is further intended to support the Company’s ability to attract and retain high-performing talent through competitive compensation, while providing flexibility in delivering appropriate incentive compensation opportunities tied to the achievement of company-wide goals.

2.					Definitions

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Confidential

LICENSE AGREEMENT

THIS LICENSE AGREEMENT (this “Agreement”) dated as of July 26, 2022 (the “Effective Date”), is entered into between Cidara Therapeutics, Inc., a Delaware corporation (“Cidara”), having a place of business at 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121, and Melinta Therapeutics, LLC, a Delaware limited liability company (together with its subsidiaries, “Melinta”), having a place of business at 44 Whippany Road, Suite 280, Morristown, NJ 07960.

WHEREAS, Cidara owns or has rightsin the Compound (as defined below).

WHEREAS, Melinta desires to obtainan exclusive license under Cidara’s rights to the Compound in the Territory (as defined below) on the terms and conditions set forth below.

NOW, THEREFORE, in considerationof the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows:

…

EXECUTION VERSION

Confidential

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

FIRST AMENDMENT TO
LICENSE AGREEMENT

THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT(“Amendment”) is entered into and effective as of April 23, 2024 (the “Amendment Date”), by and between MELINTA THERAPEUTICS, LLC, a Delaware limited liability company, having a place of business at 389 Interpace Parkway, Suite 450, Parsippany, NJ 07054 (together with its subsidiaries, “Melinta”), and CIDARA THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, USA, having its principal offices at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, USA (“Cidara”).

RECITALS

WHEREAS, Melinta and Cidara are parties to that certain License Agreement dated July 26, 2022 (the “Agreement”);

WHEREAS, Melinta and Cidara desire to make certain modifications to the terms and conditions of the Agreement; and

…

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.

CREDIT AGREEMENT

BETWEEN

ENOVUM DATA CENTERS CORP.

as Borrower

** **

AND

** **

ENOVUM MTL I GP INC., EDC MTL I LIMITED PARTNERSHIP, ENOVUM MTL II GP INC., EDC MTL II LIMITED PARTNERSHIP, ENOVUM SAINT-JEROME GP INC., EDC SAINT-JÉRÔME LIMITED PARTNERSHIP and 1504950 B.C. UNLIMITED LIABILITY COMPANY

as Guarantors

** **

AND

THE FINANCIAL INSTITUTIONS from time to time party to this Agreement and designated
as Lenders on the signature pages hereto

as Lenders

** **

AND

** **

ROYAL BANK OF CANADA

as Administrative Agent

** **

AND

** **

ROYAL BANK OF CANADA

as Sole Lead Arranger and Sole Bookrunner

---

MADE AS OF

** **

JULY 6, 2026

** **

---

** **

TABLE OF CONTENTS

…

KARYOPHARM THERAPEUTICS INC.

Restricted Stock Unit Agreement (Performance Vested)

2022 Equity Incentive Plan

NOTICE OF GRANT

This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant.

Agreement Date:
Agreement Number:

I.

Participant Information

Participant:
Participant Address:

II.

Grant Information

Grant Date:
Restricted Stock Units:

III.

Vesting Table

…

KARYOPHARM THERAPEUTICS INC.

Restricted Stock Unit Agreement

(Non-Employee Director)

2022 Equity Incentive Plan

NOTICE OF GRANT

This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant. Agreement Date and Number

Agreement Date:
Agreement Number:

(a)

Participant Information

Participant:
Participant Address:

(b)

Grant Information

Grant Date:
Number of Restricted Stock Units:

(c)

Vesting Table

…

KARYOPHARM THERAPEUTICS INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The purpose of this Non-Employee Director Compensation Policy (this “Policy”) of Karyopharm Therapeutics Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors and reflect the substantial time commitment necessary to oversee the Company’s affairs. In furtherance of this purpose, non-employee members of the board of directors (the “Board”) of the Company shall be eligible to receive cash and equity compensation as set forth in this Policy. The cash compensation and equity grants described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”), unless such Non-Employee Director declines the receipt of such cash compensation or equity grants by written notice to the Company. This Policy shall be reviewed by the Compensa

…

KARYOPHARM THERAPEUTICS INC.

Restricted Stock Unit Agreement (Performance Vested)

2022 Equity Incentive Plan

NOTICE OF GRANT

This Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Karyopharm Therapeutics Inc. (the “Company”), a Delaware corporation, and the Participant.

Agreement Date:
Agreement Number:

I.

Participant Information

Participant:
Participant Address:

II.

Grant Information

Grant Date:
Restricted Stock Units:

III.

Vesting Table

…

AMENDMENT NO. 5 TO

2022 EQUITY INCENTIVE PLAN OF

KARYOPHARM THERAPEUTICS INC.

In accordance with Section 12(d) of the 2022 Equity Incentive Plan (the “Plan”) of Karyopharm Therapeutics Inc. (the “Company”), the Plan is hereby amended, effective as of the date of approval by the Board of Directors of the Company, as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan):

1. Section 4(a)(1)(A) of the Plan be and hereby is deleted in its entirety and the following is inserted in lieu thereof:

5,406,666 shares of Common Stock; and

2. Except as expressly amended herein, the Plan and all of the provisions contained therein shall remain in full force and effect.

* * *

Approved by the Board of Directors on May 22, 2026

Approved by the Stockholders on ______ __, 202__*

…

Exhibit 10.2

THIRDAMENDMENTTOLEASE

THISTHIRDAMENDMENTTOLEASE(“Amendment”)ismadeandenteredintoasof April 14, 2026,byandbetweenBRANDYWINECIRA,L.P.,aPennsylvanialimitedpartnership ("Landlord"),andCABALETTABIO,INC.,aDelawarecorporation("Tenant”).

A.

Landlordand Tenantare parties to a Lease ("OriginalLease")dated as of February11, 2019, as amendedbya First Amendmentto Lease dated asof February 15, 2022, and a Second Amendment to Lease dated asof October 1,2024 (the OriginalLease assoamended is referred to herein asthe"CurrentLease"),for the Premises deemed tocontain 7,672 rentable square feet presently known as Suite 600 in the Building known asCira Centre located at 2929 Arch Street,Philadelphia, Pennsylvania.TheCurrentLease as amendedby this Amendmentis referredto hereinas the "Lease".

B.

The Term currently expires on June 30, 2026. Landlord and Tenant agree to amend the CurrentLease to extendthe Termupon the terms and conditions set forth herein.

…

AMENDMENT NO. 1

TO THE

CABALETTA BIO, INC. 2025 INDUCEMENT PLAN

WHEREAS, Cabaletta Bio, Inc. (the “Company”) maintains the Cabaletta Bio, Inc. 2025 Inducement Plan (the “Inducement Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”);

WHEREAS, the Board desires to amend the Inducement Plan to increase the number of shares available for issuance under the Inducement Plan;

WHEREAS, Section 16 of the Inducement Plan provides that the Board may amend the Inducement Plan at any time, subject to certain conditions set forth therein; and

NOW, THEREFORE:

1.

Section 3(a) of the Inducement Plan is hereby amended by deleting “275,000” where it appears in the first sentence thereof and replacing it with “1,275,000.”

2.

This Amendment to the Inducement Plan shall become effective upon the date that it is approved by the Board.

3.

Except as set forth above, all other provisions of the Inducement Plan shall remain

unchanged.

…